DexCom, Inc. DXCM
DexCom, Inc. is a medical device company primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems. The company serves patients, caregivers, and clinicians worldwide, providing technology to help manage diabetes and metabolic health. Its core products include the Dexcom G6 and G7 systems, which are integrated CGM devices, and Stelo, an over-the-counter glucose biosensor launched in 2024 for adults with prediabetes and Type 2 diabetes who do not use insulin. DexCom operates through a direct sales organization in North America and select international markets, complemented by distribution arrangements, to educate healthcare professionals and drive patient adoption of its monitoring solutions. The company's business model revolves around recurring revenue from disposable sensors, which comprised approximately 95% of total revenue in 2024, supported by sales of reusable hardware and ongoing investments in research and development for future generations of technology and expanded health applications.
LSTM Forecast
Forecast model is not trained yet for this market.
Train and backfill the LSTM forecast to surface a directional view here.